In addition, anti-Fn-IgA and -IgG levels were similar in both CEA-positive and CEA-negative CRC patients, or in CA19-9-positive and CA19-9-neagtive CRC patients. This evidence concerns the gene CEACAM5 and colorectal carcinoma.